会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Metaphase donor cells for effective nuclear reprogramming in mammals
    • 中期供体细胞用于哺乳动物的有效核重编程
    • US07547818B2
    • 2009-06-16
    • US10809738
    • 2004-03-25
    • Steven Stice
    • Steven Stice
    • C12N15/00
    • C12N15/873
    • The present invention provides methods of producing a clone non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include introducing doner genetic material into a metaphase I oocyte; introducing donor genetic material into a non-enucleated oocyte; introducing donor genetic material obtained from a donor cell that is a metaphase into an oocyte; introducing donor genetic material into an oocyte, and naturally activating the oocyte or the NT embryo; and introducing donor genetic material obtained from a donor cell that is at late G1 phase into anoocyte.
    • 本发明提供了产生克隆非人哺乳动物核转移(NT)胚胎的方法和用于产生克隆的非人哺乳动物的方法。 方法的实施方案包括将内含子遗传物质引入中期卵母细胞; 将供体遗传物质引入非去核卵母细胞; 将从中期的供体细胞获得的供体遗传物质引入卵母细胞; 将供体遗传物质引入卵母细胞,并自然激活卵母细胞或NT胚胎; 并将从晚期G1期的供体细胞获得的供体遗传物质引入到不孕细胞中。
    • 4. 发明申请
    • HUMAN EMBRYONIC STEM CELL DERIVED MESODERM-LIKE EPITHELIUM TRANSITIONS TO MESENCHYMAL PROGENITOR CELLS
    • 人胚胎干细胞衍生的MESODERM型上皮细胞转染到细胞祖细胞
    • US20100184212A1
    • 2010-07-22
    • US12451720
    • 2008-05-30
    • Steven SticeNolan Boyd
    • Steven SticeNolan Boyd
    • C12N5/0735C12N5/0789C12N5/077
    • C12N5/0662C12N5/0625C12N2501/105C12N2501/11C12N2501/115C12N2501/165C12N2506/02
    • Human embryonic stem cells (hESC) have the potential to produce all of the cells in the body. They are also able to self-renew indefinitely, sparking the hope they could be used as a source for large scale production of therapeutic cell lines. The present invention relates to a monolayer differentiation culture system that induces hESC (WA09 and BG01) to form epithelial sheets with mesodermal gene expression patterns (BMP4, RUNX1, GAT A4). These E-cadherin+ CD90lovv cells then undergo apparent epithelial-mesenchymal transformation (EMT) for the derivation of mesenchymal progenitor cells (hES-MC) that by flow cytometry are negative for hematopoietic (CD34, CD45 and CD 133) and endothelial (CD31 and CD 146) markers, but positive for markers associated with mesenchymal stem cells (MSC) (CD73, CD90, CD105 and CD166). To determine their functionality, we tested their capacity to produce the three lineages commonly associated with MSC and found they could form osteogenic and chondrogenic, but not adipogenic lineages. The derived hES-MC were able to remodel and contract collagen I lattice constructs to an equivalent degree as keloid fibroblast control cells and were induced to express αSMA when exposed to TGF-β1, but not PDGF-B. This data suggests the derived hES-MC cells are multipotent cells with potential uses in tissue engineering/regenerative medicine and for providing a highly reproducible cell source for adult-like progenitor cells.
    • 人类胚胎干细胞(hESC)具有产生体内所有细胞的潜力。 他们也能够无限期地自我更新,激发了他们希望将其用作大规模生产治疗性细胞系的来源。 本发明涉及诱导hESC(WA09和BG01)形成具有中胚层基因表达模式(BMP4,RUNX1,GAT A4)的上皮片的单层分化培养系统。 这些E-钙粘蛋白+ CD90lovv细胞然后经历明显的上皮 - 间质转化(EMT),用于衍生间充质祖细胞(hES-MC),其通过流式细胞术对造血(CD34,CD45和CD133)和内皮(CD31和CD 146)标记,但与间充质干细胞(MSC)(CD73,CD90,CD105和CD166)相关标志物阳性。 为了确定其功能,我们测试了其产生通常与MSC相关的三个谱系的能力,发现它们可以形成成骨和软骨形成,但不能形成脂肪形成的谱系。 衍生的hES-MC能够将胶原I晶格构建体重塑和收缩至瘢痕疙瘩成纤维细胞对照细胞的相当程度,并且当暴露于TGF-β1而不是PDGF-B时被诱导表达αSMA。 该数据表明衍生的hES-MC细胞是在组织工程/再生医学中具有潜在用途的多能细胞,并为成年样祖细胞提供高度可重复的细胞来源。
    • 10. 发明申请
    • Production of chimeric bovine or porcine animals using cultured inner cell mass
    • 使用培养的内细胞块生产嵌合牛或猪动物
    • US20060021070A1
    • 2006-01-26
    • US11024010
    • 2004-12-28
    • Steven SticeJose CibelliJames RoblPaul GoluekeF. LeonD. Jerry
    • Steven SticeJose CibelliJames RoblPaul GoluekeF. LeonD. Jerry
    • A01K67/027
    • C12N15/8771A01K2217/05C12N15/8778
    • Novel cultured inner cell mass (CICM) cells, and cell lines, derived from ungulates, in particular, pigs and cows, and methods for their preparation are provided. The subject CICMs possess similar morphology and express cell markers identically or substantially similarly to ICMs of undifferentiated developing embryos for prolonged culturing periods. Heterologous DNA is inserted into the subject CICM cells and cell lines so as produce transgenic CICM cell which are introduced into non-human fertilized embryos to produce transgenic chimeric embryos. The transgenic chimeric embryos are transferred into recipient females where they are permitted to develop into transgenic chimeric fetuses. Recipient females give birth to transgenic chimeric animals which are capable of transmitting the heterologous DNA to their progeny. Transgenic CICM cells are also used to produce cloned transgenic embryos, fetuses and offspring.
    • 提供了新颖的培养的内细胞团(CICM)细胞和源自有蹄类动物,特别是猪和牛的细胞系及其制备方法。 受试者CICM具有与未分化发育的胚胎的ICM相似或基本上类似于延长培养期的相似形态和表达细胞标记。 将异源DNA插入受试者CICM细胞和细胞系中,以产生转入非人受精胚胎以产生转基因嵌合胚胎的转基因CICM细胞。 将转基因嵌合胚胎转移到受体雌性中,在其中允许其转化为转基因嵌合胎儿。 受体女性产生能够将异源DNA转移到其后代的转基因嵌合动物。 转基因CICM细胞也用于产生克隆的转基因胚胎,胎儿和后代。